description
Powered by Eupheria Biotech
Quality Level
product line
MISSION®
form
lyophilized powder
esiRNA cDNA target sequence
GATGGTCCTGTCCATCTGCTTGTGCCGGCACGTCCATTCCGAAGACTACAGCAAGGTCCCCAAGTACTGAGGCAGCTGCTATCCCCATCTCCCTGCCTGGCCCCCAACCTCAGGGCTCCCAGGGGTCTCCCTGGCTCCCTCCTCCAGGCCTGCCTCCCACTTCACTGCGAAGACCCTCTTGCCCATCCTGACTGAAAGTAGGGGGCTTTCTGGGGCCTAGCGATCTCTCCTGGCCTATCCGCTGCCAGCCTTGAGCCCTGGCTGTTCTGTGGTTCCTCTGCTCACCGCCCATCAGGGTTCTCTTAGCAACTCAGAGAAAAATGCTCCCCACAGCGTCCCTGGCGCAGGTGGGCTGGACTTCTACCTGCCCTCAAGGGTGTGTATATTGTATAGGGGCAACTGTATGAAAAATTGGGGAGGAGGGGGCCGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAG
Ensembl | human accession no.
NCBI accession no.
shipped in
ambient
storage temp.
−20°C
Gene Information
human ... CD82(3732)
General description
MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
Legal Information
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Jianwen Long et al.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 102, 1195-1202 (2018-05-02)
Melanoma has been a severe threat to human health, microRNAs play vital roles in the oncogenesis and progression of cancers. In this report, the roles and mechanism of miR-338-5p were investigated in the development of melanoma. A total of 46
Muskan Floren et al.
Oncogene, 39(19), 3910-3925 (2020-03-24)
A principal challenge in treating acute myeloid leukemia (AML) is chemotherapy refractory disease. As such, there remains a critical need to identify key regulators of chemotherapy resistance in AML. In this study, we demonstrate that the membrane scaffold, CD82, contributes
Thomas B Layton et al.
Nature communications, 11(1), 2768-2768 (2020-06-04)
Fibrotic disorders are some of the most devastating and poorly treated conditions in developed nations, yet effective therapeutics are not identified for many of them. A major barrier for the identification of targets and successful clinical translation is a limited
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| EHU064501-20UG | 04061828607228 |
| EHU064501-50UG | 04061828382163 |